Completed PHASE3 INTERVENTIONAL NCT00206141

Seroquel in Bipolar Depression Versus Lithium

Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)

Sponsor: AstraZeneca

Conditions Bipolar Depression Bipolar Disorder Depression

Interventions Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)

Updated 6 times since 2017 Last updated: Jan 3, 2013 Started: Aug 31, 2005 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00206141, this PHASE3 trial focuses on Bipolar Depression and Bipolar Disorder and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia , Belgrade, Serbia , Berlin, Germany , Bialystok, Poland , Brattvåg, Norway , Bydgoszcz, Poland , Changhua, Taiwan , Daugavpils, Latvia , Davao City, Philippines , Dnipropetrovsk, Ukraine and 66 more locations